News from 2010

Seroba Kernel Announces €4.7m Financing into Provesica to Complete Phase 2 Trial for Overactive Bladder

Demerger and financing of Xention’s OAB program in Provesica Dublin, Ireland, December 2010: Seroba Kernel Life Sciences announced today that, as a follow-on to its recent investment into Xention Ltd, along with Forbion Capital Partners - a further €4.7m has been invested into Prov

Seroba Kernel leads €4.8m investment in Covagen

Covagen receives €4.8m Series A funding for its next generation protein drugs for the treatment of inflammatory diseases and cancer  Zurich, Switzerland, November 29, 2010: Covagen, an ETH Zurich spin-off company pioneering the development of a novel class of protein therapeutics (Fynomer

Seroba Kernel Leads an €8.5 Million Financing in Xention

Funds to progress novel heart arrhythmia drugs through clinical proof of concept Dublin, Ireland, 23 November 2010: Seroba Kernel Life Sciences announced today that it has led an €8.5 million Series D equity investment in the Cambridge-based biopharmaceutical company, Xention Ltd. Xention spec